These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35714883)

  • 1. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of mepolizumab in patients with high-burden severe asthma within a managed care population.
    Lugogo NL; Bogart M; Corbridge T; Packnett ER; Wu J; Hahn B
    J Asthma; 2023 Apr; 60(4):811-823. PubMed ID: 35853158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis.
    Silver J; Molfino N; Bogart M; Packnett ER; McMorrow D; Wu J; Hahn B
    Clin Ther; 2021 Dec; 43(12):2064-2073. PubMed ID: 34893348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Mepolizumab on Exacerbations in the US Medicare Population.
    Sethi S; Bogart M; Corbridge T; Cyhaniuk A; Hahn B
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):546-554.e2. PubMed ID: 36377070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
    Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
    Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).
    Al-Lehebi RO; Al Ahmad M; Maturu VN; Mesa AG; Mahboub B; Garcia E; Fernandez P; Soares C; Abreu G; Dos Santos D; Queiroz J; Raimondi A; Laucho-Contreras M; Noibi S; Levy G; Bavbek S
    Adv Ther; 2024 Nov; 41(11):4008-4031. PubMed ID: 39215767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study.
    Fukunaga K; Tagaya E; Ishida M; Sunaga Y; Koshiba R; Yokoyama A
    Allergol Int; 2023 Oct; 72(4):537-544. PubMed ID: 37117134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma.
    Silver J; Bogart M; Packnett E; Wu J; McMorrow D; Hahn B
    J Asthma Allergy; 2020; 13():689-699. PubMed ID: 33364788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma.
    Pilette C; Canonica GW; Chaudhuri R; Chupp G; Lee FE; Lee JK; Almonacid C; Welte T; Alfonso-Cristancho R; Jakes RW; Maxwell A; Price RG; Howarth P
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2646-2656. PubMed ID: 35753668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery.
    Silver J; Deb A; Laliberté F; Gao C; Bhattacharyya N
    Int Forum Allergy Rhinol; 2024 Jan; 14(1):5-17. PubMed ID: 37365852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
    Casale T; Molfino NA; Silver J; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):354-362.e2. PubMed ID: 34038773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
    Llanos JP; Ortega H; Bogart M; Packnett ER; Manjelievskaia J; Bell CF; Hahn B
    J Asthma Allergy; 2020; 13():77-87. PubMed ID: 32099413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab.
    Corren J; Silver J; Molfino NA; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
    Ann Allergy Asthma Immunol; 2022 Feb; 128(2):184-192.e1. PubMed ID: 34774737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.
    Harrison T; Canonica GW; Chupp G; Lee J; Schleich F; Welte T; Valero A; Gemzoe K; Maxwell A; Joksaite S; Yang S; Howarth P; Van Dyke MK
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32817259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review.
    Israel E; Canonica GW; Brusselle G; Yang S; Howarth PH; Martin AL; Koufopoulou M; Smith SG; Alfonso-Cristancho R
    J Asthma; 2022 Nov; 59(11):2201-2217. PubMed ID: 34951336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
    Matucci A; Vivarelli E; Bormioli S; Francesca N; Chiccoli F; Valentina M; Francesca G; Oliviero R; Parronchi P; Vultaggio A
    J Asthma; 2023 Jan; 60(1):158-166. PubMed ID: 35112934
    [No Abstract]   [Full Text] [Related]  

  • 19. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world unified airway benefits of mepolizumab: Effectiveness in patients with asthma and comorbid nasal polyps.
    Bernstein JA; Silver J; Packnett E; Lew CR; Robles Y; Deb A
    Ann Allergy Asthma Immunol; 2024 Oct; 133(4):422-429.e2. PubMed ID: 38972449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.